Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.
- Authors
- Choueiri, TK[Choueiri, Toni K.]; Tomczak, P[Tomczak, Piotr]; Park, SH[Park, Se Hoon]; Venugopal, B[Venugopal, Balaji]; Ferguson, T[Ferguson, Tom]; Symeonides, SN[Symeonides, Stefan N.]; Hajek, J[Hajek, Jaroslav]; Chang, YH[Chang, Yen-Hwa]; Lee, JL[Lee, Jae-Lyun]; Sarwar, N[Sarwar, Naveed]; Thiery-Vuillemin, A[Thiery-Vuillemin, Antoine]; Gross-Goupil, M[Gross-Goupil, Marine]; Mahave, M[Mahave, Mauricio]; Haas, NB[Haas, Naomi B.]; Sawrycki, P[Sawrycki, Piotr]; Xu, L[Xu, Lei]; Imai, K[Imai, Kentaro]; Willemann-Rogerio, J[Willemann-Rogerio, Jacqueline]; Quinn, DI[Quinn, David I.]; Powles, T[Powles, Thomas]
- Issue Date
- 20-Feb-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.6
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 6
- URI
- https://scholarx.skku.edu/handle/2021.sw.skku/96396
- DOI
- 10.1200/JCO.2022.40.6_suppl.290
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.